Subscribe to RSS
DOI: 10.1055/s-0034-1372644
Effects of Escitalopram on Plasma Concentrations of Aripiprazole and its Active Metabolite, Dehydroaripiprazole, in Japanese Patients
Publication History
received 06 February 2014
revised 20 March 2014
accepted 20 March 2014
Publication Date:
24 April 2014 (online)
Abstract
Introduction: The effects of escitalopram (10 mg/d) coadministration on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, were studied in 13 Japanese psychiatric patients and compared with those of paroxetine (10 mg/d) coadministration.
Methods: The patients had received 6–24 mg/d of aripiprazole for at least 2 weeks. Patients were randomly allocated to one of 2 treatment sequences: paroxetine-escitalopram (n=6) or escitalopram-paroxetine (n=7). Each sequence consisted of two 2-week phases. Plasma concentrations of aripiprazole and dehydroaripiprazole were measured using liquid chromatography with mass spectrometric detection.
Results: Plasma concentrations of aripiprazole and the sum of aripiprazole and dehydroaripiprazole during paroxetine coadministration were 1.7-fold (95% confidence intervals [CI], 1.3–2.1, p<0.001) and 1.5-fold (95% CI 1.2–1.9, p<0.01) higher than those values before the coadministration. These values were not influenced by escitalopram coadministration (1.3-fold, 95% CI 1.1–1.5 and 1.3-fold, 95% CI 1.0–1.5). Plasma dehydroaripiprazole concentrations remained constant during the study.
Conclusion: The present study suggests that low doses of escitalopram can be safely coadministered with aripiprazole, at least from a pharmacokinetic point of view.
-
References
- 1 Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-1411
- 2 Harrison TS, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 1715-1736
- 3 Jordan I, Robertson D, Catani M et al. Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder. Psychopharmacolgy 2012; 223: 357-360
- 4 Caccia S. N-Dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 2007; 8: 612-622
- 5 Kubo M, Koue T, Inaba A et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20: 55-64
- 6 Suzuki T, Mihara K, Nakamura A et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2011; 33: 21-24
- 7 Kirschbaum KM, Müller MJ, Malevani J et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008; 9: 212-218
- 8 Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol 2003; 18: 305-313
- 9 Nemoto K, Mihara K, Nakamura A et al. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2012; 34: 188-192
- 10 Preskorn SH, Greenblatt DJ, Flockhart D et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychoph/armacol 2007; 27: 28-34
- 11 Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007; 40: 107-110
- 12 Waade RB, Christensen H, Rudberg I et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009; 31: 233-238
- 13 Kubo M, Koue T, Maune H et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007; 22: 358-366
- 14 Guy W. Clinical Global Impressions. Guy W (ed.). ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: US Department of Health, Education and Welfare; 1976: 217-222
- 15 Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated olanzapine or haloperidol. Schizophr Res 2002; 57: 227-238
- 16 Kubo M, Mizooku Y, Hirao Y et al. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatography B 2005; 822: 294-299
- 17 Steen VM, Andreassen OA, Daly AK et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-223
- 18 Heim M, Meyer U. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532
- 19 Johansson I, Oscarson M, Yue QY et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-459
- 20 Kubota T, Yamaura Y, Ohkawa N et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000; 50: 31-34
- 21 Kimura M, Ieiri I, Urae K et al. Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population. Ther Drug Monit 1998; 20: 243-247
- 22 Sakuyama K, Sasaki T, Ujiie S et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47–51, 53–55, and 57). Drug Metab Dispos 2008; 36: 2460-2467